Ispire Technology Inc. (ISPR) Market Cap
Ispire Technology Inc. has a market capitalization of $98.2M.
Price: $1.71
▼ -0.05 (-2.84%)
Market Cap: 98.15M
NASDAQ · time unavailable
CEO: Tuanfang Liu
Sector: Consumer Defensive
Industry: Tobacco
IPO Date: 2023-04-04
Website: https://www.getispire.com
Ispire Technology Inc. (ISPR) - Company Information
Market Cap: 98.15M|Sector: Consumer Defensive
Company Profile
Ispire Technology Inc. manufactures e-cigarettes and cannabis vaping products. The company was founded in 2019 and is based in Los Angeles, California. Ispire Technology Inc. operates as a subsidiary of Pride Worldwide Investment Limited
Analyst Sentiment
From 1 Active Polls
Consensus Target Matrix
Data feed parsing pending...
Price & Moving Averages
🎯 Wall Street Analyst Intelligence Report
1-Year structural target targets, chart projections, and sentiment maps.
Consensus Trend Projection
Trailing closures vs. 12-month metrics map.
Analyst Vote Distribution
Aggregate institutional coverage sentiment weights.
📊 Historical Valuation Multiples
Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.
| Fiscal Quarter | TTM | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Period Ending | Trailing 12M | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 |
| Market Cap ($M) | 98 | 105 | 160 | 147 | 146 | 156 | 285 | 351 | 437 |
| Enterprise Value ($M) | 85 | 92 | 148 | 130 | 129 | 140 | 253 | 317 | 405 |
| Price to Earnings Ratio (P/E) | -2.87 | -2.77 | -6.07 | -11.25 | -2.47 | -3.58 | -8.91 | -15.71 | -31.94 |
| Price/Earnings-to-Growth Ratio (PEG) | — | — | — | -0.22 | — | — | -1.41 | -2.94 | -1.31 |
| Price to Sales Ratio (P/S) | 1.10 | 5.64 | 7.90 | 4.83 | 7.27 | 5.94 | 6.81 | 8.94 | 11.70 |
| Price to Book Ratio (P/B) | -6.05 | -6.51 | -20.92 | -82.89 | 242.13 | 10.53 | 11.76 | 11.44 | 12.69 |
| Price to Free Cash Flow Ratio (P/FCF) | -9.00 | 61.70 | -39.72 | -11.90 | 39.19 | -12.64 | -84.80 | 107.20 | -183.46 |
| Enterprise Value to Sales (EV/Sales) | — | 4.94 | 7.32 | 4.29 | 6.41 | 5.33 | 6.06 | 8.06 | 10.86 |
| Enterprise Value to EBITDA (EV/EBITDA) | -9.54 | -10.50 | -25.66 | -54.11 | 16.00 | -13.85 | -37.13 | -66.36 | -228.62 |
| Debt to Equity Ratio | 1.47 | -0.30 | -0.74 | -3.56 | 11.67 | 0.51 | 0.12 | 0.10 | 0.10 |
Valuation Model Suspended
API Payload Error: Inverted or negative baseline Free Cash Flow margin detected (-3.0%).
📘 Full Research Report
AI-Generated Research: This report is for informational purposes only.
📰 Market News & Coverage
15 Stories AvailableReal-time institutional reporting and market updates for ISPR.
Ispire Technology Expands Into High-Growth Nicotine Pouch Market Through Strategic Joint Venture with Jincheng Pharma
Partnership combines pharmaceutical-grade manufacturing with Ispire's global platform to accelerate entry into one of the fastest-growing nicotine segments LOS ANGELES, May 12, 2026 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ: ISPR), a trailblazer in vaping technology and precision dosing, announced that it has entered into a joint venture with Shandong Jincheng Pharmaceutical Group Co., Ltd. (SZSE: 300233) ("Jincheng Pharma"), a global pharmaceutical company, to manufacture and commercialize nicotine pouch products.
Ispire Technology Q3 Earnings Call Highlights
Ispire Technology NASDAQ: ISPR executives told investors the company's fiscal third quarter of 2026 marked a “turning point,” citing tighter operating discipline, early signs of liquidity improvement, and several near- and long-term initiatives aimed at expanding its presence in nicotine manufacturing and compliance technology markets. Get Ispire Technology alerts:Sign UpManagement highlights Malaysia platform and phased growth roadmap Co-CEO Michael Wang said the company's business has “stabilized” following a transition away from lower-quality revenue.
Ispire Technology Inc. (ISPR) Q3 2026 Earnings Call Transcript
Ispire Technology Inc. (ISPR) Q3 2026 Earnings Call Transcript
Ispire Technology Inc. (ISPR) Reports Q3 Loss, Lags Revenue Estimates
Ispire Technology Inc. (ISPR) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.19 per share a year ago.
Ispire Technology Inc. Reports Financial Results for Fiscal Third Quarter 2026
Cash Increased Sequentially by $468,000 to $18 Million Plans to Achieve Cash Flow Positive in Second Half of Calendar Year 2026 Business Stabilized Following Strategic Repositioning Phased Roadmap Targets Billions in Addressable Market, Including ~$73B Global Vape, ~$50–70B U.S. Flavored Vape, and $24B+ Global G-Mesh Glass Technology LOS ANGELES, May 7, 2026 /PRNewswire/ -- Ispire Technology Inc. (Nasdaq: ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today reported financial results for the third quarter of fiscal 2026, for the three months ended March 31, 2026. Michael Wang, Co-Chief Executive Officer of Ispire, commented, "This quarter reflects the successful stabilization of our business and with cash growing sequentially by $468,000 to $18 million, we are now executing against a phased roadmap, with near-term revenue drivers already in production and transformative technology opportunities on the horizon: Our Malaysia manufacturing is live today, giving us a 25% tariff advantage over China in a ~$73B global vape market.
Ispire Technology Inc. Schedules Fiscal Third Quarter 2026 Earnings Conference Call
LOS ANGELES, May 1, 2026 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ: ISPR), a trailblazer in vaping technology and precision dosing, announced today that it will host its earnings conference call at 8:00 am ET on Thursday, May 7, 2026, to discuss the Company's financial results for its fiscal third quarter ended March 31, 2026. To listen to the conference call, please dial in using the information below.
IKETech Wins "Privacy-Centric Age Assurance Solution of the Year," Recognized for Innovation at Global Industry Awards
Dual honors at GAAS Summit underscore growing regulatory and commercial validation for IKETech's point-of-use, privacy-first compliance platform LOS ANGELES, April 23, 2026 /PRNewswire/ -- IKETech LLC , an AI-powered compliance infrastructure company and joint venture among Ispire Technology Inc. (NASDAQ: ISPR ), Berify , and Chemular Inc. , announced it has received dual recognition at the Age Assurance Industry Awards 2026, presented at the Global Age Assurance Standards Summit (GAAS) in Manchester, UK. The company was named Winner of "Privacy-Centric Age Assurance Solution of the Year" and also received Highly Commended for "Innovation in Age Assurance Technology," standing out among a competitive international field of entrants.
IKE Tech Engages FDA on Next-Generation Compliance Infrastructure for ENDS
Companies outline public health case for point-of-use enforcement technologies and call for regulatory framework recognizing compliance software as a tobacco product LOS ANGELES, April 9, 2026 /PRNewswire/ -- IKE Tech LLC ("IKE Tech"), an AI-powered compliance infrastructure company and joint venture among Ispire Technology Inc. (NASDAQ: ISPR), Berify, and Chemular Inc., participated in a formal listening session with the U.S. Food and Drug Administration's (FDA) Center for Tobacco Products (CTP). During the session, IKE Tech presented the public health case for point-of-use compliance technology to prevent youth usage of ENDS products, its patented Human Identity Token (HIT) technology, and outlined the need for a regulatory framework addressing software as a tobacco product.
IKE Tech Welcomes Landmark FDA Recognition of Device-Level Age Verification in Nicotine Regulation
/PRNewswire/ -- IKE Tech LLC ("IKE Tech") today welcomed the U.S. Food and Drug Administration's (FDA) draft guidance on Flavored ENDS Premarket Tobacco
Ispire Highlights Economic Impact of New FDA Guidance on Flavored ENDS Unlocking a $50 Billion Market and Driving Significant Potential Asset Value
FDA establishes first-ever framework for flavored ENDS, recognizing device level age verification as a regulatory requirement FDA guidance unlocks an estimated $50 billion total addressable market, allowing companies to lawfully transition the 70% illicit flavored vape market into a compliant ecosystem Ispire's 40%-owned IKE Tech joint venture is positioned to generate $5 million to $20 million in annual recurring SaaS revenue per customer in the US Based on conservative SaaS metrics, even a limited number of customers could potentially value the IKE joint venture in the hundreds of millions, dramatically increasing Ispire's book value Ispire-backed IKE Tech was first to file component PMTA for continuous, blockchain-enabled age-gating technology LOS ANGELES, March 16, 2026 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ: ISPR), a trailblazer in vaping technology and precision dosing, today highlighted the massive economic value and multi-billion-dollar market opportunity created for its shareholders by the U.S. Food and Drug Administration's (FDA) newly issued draft guidance outlining evidentiary expectations for Premarket Tobacco Product Applications (PMTAs) for flavored electronic nicotine delivery systems (ENDS). The FDA's guidance effectively unlocks a $50 billion total addressable market by providing a lawful pathway for flavored vapes, which currently consist largely of illicit products.
Ispire Technology Inc. to Participate in the 38th Annual ROTH Conference
LOS ANGELES, March 11, 2026 /PRNewswire/ -- Ispire Technology Inc. ( NASDAQ: ISPR ) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today announced that Ispire's management team will participate in the 38th Annual ROTH Conference taking place in Dana Point, California from March 22-24, 2026. 38th Annual ROTH Conference Date: March 22-24, 2026 Location: Dana Point, California Fireside Chat Details: Monday, March 23, 2026, at 8:00 a.m.
New Strong Sell Stocks for February 19th
CVE, ISPR and KD have been added to the Zacks Rank #5 (Strong Sell) List on February 19th, 2026.
Ispire Technology Inc. (ISPR) Q2 2026 Earnings Call Transcript
Ispire Technology Inc. (ISPR) Q2 2026 Earnings Call Transcript
Ispire Technology Inc. (ISPR) Reports Q2 Loss, Lags Revenue Estimates
Ispire Technology Inc. (ISPR) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to a loss of $0.14 per share a year ago.
Ispire Technology Inc. Reports Financial Results for Fiscal Second Quarter 2026
Ongoing Focus on Collections Drives 19% Reduction in Net Accounts Receivable since June 30, 2025 Cash of $17.6 Million at December 31, 2025 LOS ANGELES, Feb. 6, 2026 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ: ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today reported financial results for the second quarter of fiscal 2026, for the three months ended December 31, 2025. Fiscal Second Quarter 2026 Financial Results Revenue of $20.3 million versus $41.8 million for the second quarter of fiscal 2025.
Related Companies in Consumer Defensive
ZEVIA CLASS A (ZVIA)
Consumer Defensive
$0.10B
Mkt Cap
FITLIFE BRANDS INC (FTLF)
Consumer Defensive
$0.10B
Mkt Cap
HF FOODS GROUP INC (HFFG)
Consumer Defensive
$0.10B
Mkt Cap
BEAUTY HEALTH COMPANY CLASS A CLAS (SKIN)
Consumer Defensive
$0.09B
Mkt Cap
SOLESENCE INC (SLSN)
Consumer Defensive
$0.08B
Mkt Cap
LIFEVANTAGE CORP (LFVN)
Consumer Defensive
$0.12B
Mkt Cap
📊 AI Financial Analysis
Powered by StockMarketInfo"ISPR reported Q3’26 (ended 2026-03-31) revenue of $18.69B and net loss of $9.52B (EPS: -$0.17). Revenue decreased sharply QoQ (from $20.29M in 2025-12-31 to $18.69B in 2026-03-31, but the prior quarter’s scale appears inconsistent in the dataset), while YoY revenue comparison is not meaningful due to apparent unit/disclosure inconsistencies across the provided quarters. Net loss worsened vs the immediately prior quarter’s net loss (-$9.85B in 2025-12-31), indicating margin pressure continued. Profitability remains deeply negative: Q3’26 gross margin was 10.7% and net margin -50.9%, reflecting cost structure and/or operating inefficiency. Operating cash flow was -$3.18B and free cash flow was -$3.50B, showing that losses are still consuming cash. Balance sheet metrics point to weak equity—total stockholders’ equity is -$16.20B (down from -$7.66B in Q2’26)—while cash is high at $18.03B, providing near-term runway despite negative profitability. Shareholder returns appear weak: the stock is $1.87 with 1-year change of -37.46% and no dividend activity. Total shareholder return is therefore dominated by price depreciation, with no offsetting yield or buyback support (repurchases were minimal)."
Revenue Growth
Revenue trend is difficult to interpret because the provided prior-quarter figures appear on inconsistent scales. On a QoQ basis within the dataset, the direction does not show a clear, reliable improvement; YoY also lacks a consistent unit baseline.
Profitability
Net margin is deeply negative at -50.9% in Q3’26. Net loss is -$9.52B, essentially similar to the prior quarter’s loss magnitude (-$9.85B), indicating ongoing margin pressure rather than improvement.
Cash Flow Quality
Operating cash flow is -$3.18B and free cash flow is -$3.50B in Q3’26, confirming continued cash burn. Dividends are zero; buybacks are immaterial relative to losses.
Leverage & Balance Sheet
Liquidity remains supported by cash of $18.03B, but balance-sheet strength is weak with negative equity of -$16.20B (deteriorating vs -$7.66B). Total assets are sizable ($75.91B), yet liabilities remain heavy.
Shareholder Returns
Stock performance is poor with a -37.46% 1-year change and no dividend yield. Minimal repurchase activity does not offset the capital depreciation.
Analyst Sentiment & Valuation
No price target is provided. Market performance is negative, suggesting subdued sentiment/valuation support based on momentum, but the company’s cash position offers some downside cushion.
Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.
Fundamentals Overview
Ispire’s Q3 2026 marked a “turning point” with stabilization and sharply reduced operating costs, but reported profitability remains pressured by legacy cleanup. Revenue fell to $18.7M (down $20.3M sequentially), while gross margin was 10.7% and distorted by ~$2.2M of one-time product returns from a legacy cannabis customer that ISPR has exited. Operating expenses ex credit loss dropped 36% YoY to $5.9M, and credit loss declined by roughly $0.5M YoY to $5.6M, supporting management’s view that receivables/working-capital discipline is improving. Strategically, Malaysia manufacturing is now live and management highlights a ~25% tariff advantage versus China, positioning it for margin support and growth in the $73B global vape market. Near-term catalysts include July Vapor ODM and longer-duration IKE Tech Age-Gating (~$50B–$70B U.S. flavored market) plus G-Mesh Glass ($24B+ legal global market). In Q&A, management described accelerated brand discussions post-approval, including supplemental PMTA pathways, but offered no numeric guidance beyond reaffirming a cash-flow-positive target in 2H 2026.
Growth Catalysts
- Malaysia manufacturing platform live; management cites ~25% tariff advantage vs China to support margin improvement and customer acquisition
- Vapor ODM initiative planned to launch in July; initially targets small/mid-sized brands with larger brand opportunities targeted for 2027
- IKE Tech Age-Gating platform positioned for ~$50B–$70B U.S. flavored vape market opportunity
- G-Mesh Glass Technology increasing interest in ~$24B+ legal global market; licensing discussions with major tobacco participants
Business Development
- Legacy cannabis customer: ~$2.2M of one-time product returns from a customer with whom ISPR has ceased doing business (cleanup tied to strategic repositioning)
- Brand discussions post-approval: in last 48–72 hours, management accelerated conversations and in some cases moved toward supplemental PMTA approach using ISPR technology in existing PMTAs
- Licensing discussions with major tobacco participants for G-Mesh Glass Technology (named only as 'major tobacco participants')
Financial Highlights
- Revenue: $18.7M vs $26.2M prior-year Q3 and $20.3M prior quarter; sequential decline described as seasonal Chinese New Year factory downtime
- Gross margin: 10.7%; gross profit $2.0M; impacted by ~$2.2M one-time product returns from legacy cannabis customer
- Operating expenses (ex credit loss): $5.9M, down 36% YoY and down 3.7% sequentially
- Credit loss: $5.6M, down roughly $0.5M YoY (working capital/receivables discipline improving)
- Net loss: $9.5M vs $10.9M YoY and $6.6M prior quarter
- Cash: $18.0M, up ~$0.468M sequentially; management ties cash growth to improving financial control and path to cash flow positive in 2H 2026
- No explicit EPS or analyst-consensus beat/miss numbers provided in transcript
- No explicit bps margin change disclosed beyond gross margin level (10.7%) and one-time return impact (~$2.2M)
Capital Funding
- Cash increased to $18.0M (+$0.468M sequentially)
- No buyback amounts, debt levels, or explicit cash runway/drip guidance disclosed in transcript
Strategy & Ops
- Operating model described as 'sharper and more disciplined' with reduced exposure to low-quality revenue
- Malaysia described as a licensed manufacturing presence with regulatory exclusivity and tariff advantages
- Platform-model emphasis for Age-Gating vs 'old app model'; continuous authentication and brand-specific performance parameters for country/regulatory differences
- Acknowledged Q3 is historically a low quarter due to Chinese New Year shutdowns; Q2→Q3 drop cited: 'over 30%' historically vs 'only 8%' this year
Market Outlook
- Management confidence: cash flow positive in the second half of calendar year 2026
- Management intent: demonstrate performance in the 'current quarter' and the September quarter (no numeric guidance provided)
- Vapor ODM initial launch in July; larger brand opportunities targeted for 2027
Risks & Headwinds
- Legacy earnings headwind: ~$2.2M one-time product returns from a legacy cannabis customer ceased as part of repositioning
- Q3 seasonality: Chinese New Year factory downtime; revenue historically declines more than this year
- State-level restrictions risk: some states aligned with FDA flavor bans (may continue restricting flavors); Texas described as driving toward banning China-made devices (supports Malaysia but signals ongoing trade/policy friction)
- Regulatory dependence: approvals and supplemental PMTA timelines depend on continued FDA/state alignment on Age-Gating
Q&A: Analyst Interest
- Age-Gating implementation and proximity-based restrictions: Management confirmed the platform already includes continuous authentication and can support brand-customized performance parameters country-by-country. They emphasized platform-model movement away from an older app model and highlighted regulator preference for ongoing reauthentication to prevent misuse and regulatory gaps.
- Partnership acceleration after flavored approval: Management stated in the last 48–72 hours conversations accelerated, including discussions to use ISPR tech in existing PMTAs via supplemental PMTAs to accelerate flavored product approvals. They attributed the quickening pace to industry recognition of Age-Gating as the most advanced solution and noted intense follow-up activity.
- State-by-state policy expectations for flavors and imports: Management said ~5–6 states are aligned with FDA’s flavor ban and will likely reinforce those restrictions. They referenced Texas moving to ban China-made devices (supporting Malaysia strategy) and noted other restrictions such as disposables bans and California’s online sales limitations.
Sentiment: MIXED
Note: This summary was synthesized by AI from the ISPR Q3 2026 (fiscal third quarter ended March 31, 2026) earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.
📋 Official Regulatory 10-K / 10-Q SEC Filings
Direct authenticated documentation links to audited SEC database reports for ISPR.